On April 30, 2018 RhoVac AB ("RhoVac") reported that the company will be presenting at Aktiespararnas Aktiefrukost in Stockholm, Sweden and at 3rd Annual Advances in Immuno Oncology Congress, London, UK (Press release, RhoVac, APR 30, 2018, View Source [SID1234525838]). In June, RhoVac will attend the International Convention, Boston, USA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RhoVac’s CEO Anders Ljungqvist will present status and plans for the company’s drug candidate RV001 at Aktiespararnas Aktiefrukost, Operatorrassen, Stockholm, Sweden May 3, 2018. Registration for this event is via View Source

Anders Ljungqvist will attend 3rd Annual Advances in Immuno-Oncology Congress 24-25 May 2018 in London, UK (View Source). Not only research institutes, but also global pharmaceutical companies and biotechnology companies are attending this conference.

RhoVac will also attend the Biotechnology Innovation Organization’s (BIO) Conference International Convention, Boston, USA, between 4-7 June 2018. At BIO more than 1100 biotechnology companies, academic institutions and other related organizations from USA and over 30 other countries are represented.

For more information, please contact:
Anders Ljungqvist – VD, RhoVac AB
Phone: +45 4083 2365
E-mail: [email protected]